The Healthcare & Life Sciences market has undergone dramatic change over the last several years, with a paradigm shift from a fee-for-service to a fee-for-value environment in the United States. At the same time, pharmaceutical and device manufacturers are facing price pressures across Europe and dealing with the entry of disruptive substitutes like biosimilars and reprocessed medical devices.

The dynamic Healthcare & Life Sciences landscape necessitates robust investment in new and novel growth pathways.